GLP-1 medications could support cancer treatment
Recent research suggests that GLP-1 medications such as semaglutide, originally developed for diabetes and known as a weight loss agent, may also have potential cancer-inhibiting properties. Multiple studies are investigating these new potential applications beyond their previously known effects. The article analyzes four key questions regarding this promising research development.